The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics

被引：0
|
作者：
Singh, Dave
Leaker, Brian
Boyce, Malcom
Nandeuil, Marie -Anna
Collarini, Sara
Mariotti, Fabrizia
Santoro, Debora
Barnes, Peter J.
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2014年 / 44卷
关键词：
Anti-inflammatory; COPD; -; management; Pharmacology;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile
    Facchinetti, Fabrizio
    Moretto, Nadia
    Caruso, Paola
    Marchini, Gessica
    Bosco, Raffaella
    Carnini, Chiesa
    Civelli, Maurizio
    Villetti, Gino
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [22] Chf6001 Is A Novel Highly Potent And Selective Phosphodiesterase 4 (pde4) Inhibitor With A Robust In Vitro Anti-Inflammatory Profile
    Moretto, N.
    Caruso, P.
    Marchini, G.
    Bosco, R.
    Carnini, C.
    Civelli, M.
    Villetti, G.
    Facchinetti, F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [23] The Effects of PDE4 Inhibitors Roflumilast and CHF6001 on Cytokine Production from COPD BAL Lymphocytes
    Lea, S.
    Hodgson, L.
    Southworth, T.
    Facchinetti, F.
    Villetti, G.
    Civelli, M.
    Singh, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [24] The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients
    Lea, Simon
    Metryka, Alexandra
    Li, Jian
    Higham, Andrew
    Bridgewood, Charles
    Villetti, Gino
    Civelli, Maurizio
    Facchinetti, Fabrizio
    Singh, Dave
    CYTOKINE, 2019, 123
  • [25] The PDE4 inhibitor CHF-6001 and LAMAs inhibit bronchoconstriction-induced remodeling in lung slices
    Kistemaker, Loes E. M.
    Oenema, Tjitske A.
    Baarsma, Hoeke A.
    Bos, I. Sophie T.
    Schmidt, Martina
    Facchinetti, Fabrizio
    Civelli, Maurizio
    Villetti, Gino
    Gosens, Reinoud
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2017, 313 (03) : L507 - L515
  • [26] Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD
    Singh, Dave
    Nandeuil, Marie Anna
    Pigeon-Francisco, Catherine
    Emirova, Aida
    Santoro, Debora
    Biondaro, Sonia
    Govoni, Mirco
    Petruzzelli, Stefano
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [27] Combined Effects of the Phosphodiesterase Type 4 (PDE4) Inhibitor, Roflumilast, and the PDE5 Inhibitor, Tadalafil, in Allergen-Induced Airway Hyperresponsiveness (AHR).
    Takeda, K.
    Shiraishi, Y.
    Domenico, J.
    Loader, J. E.
    Sanjar, S.
    Lucas, J. J.
    Gelfand, E. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [28] Anti-inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus-inducible cytokines
    Edwards, Michael R.
    Facchinetti, Fabrizio
    Civelli, Maurizio
    Villetti, Gino
    Johnston, Sebastian L.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2016, 4 (01):
  • [29] Effect of a novel PDE4 inhibitor AWD 12-281 on allergen-induced contractions in passively sensitized human airways
    Schmidt, D
    Szelenyi, I
    Poppe, H
    Magnussen, P
    Rabe, KF
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A854 - A854
  • [30] The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1-and Th17-polarizing cytokines in human dendritic cells
    Gianello, Veronica
    Salvi, Valentina
    Parola, Carmen
    Moretto, Nadia
    Facchinetti, Fabrizio
    Civelli, Maurizio
    Villetti, Gino
    Bosisio, Daniela
    Sozzani, Silvano
    BIOCHEMICAL PHARMACOLOGY, 2019, 163 : 371 - 380
12345